Summarized by Masters of Longevity from Longevity Technology.
Alzheimer’s drug and diagnostic development: a news piece about a company launching a mid-stage vaccine trial while also advancing a blood-based test, offering context on program plans and partnerships.
Key Takeaways
- The company initiated operational start-up for a global Phase II program of its therapeutic vaccine and expects first enrollment around late 2026 or early 2027.
- A completed Phase Ib study reportedly showed favorable safety, durable Aβ-specific immune responses, and exploratory cognitive and biomarker stabilization versus historical controls.
- The company is advancing an Aβ42CC blood-based diagnostic in collaboration with Amsterdam UMC and has a letter of intent with Fujirebio for commercialization.
